Test Type: CHRONIC

Route: IN-UTERO

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Species/Strain: MICE/B6C3F1/NCTR

C Number: C20311

Lock Date: 12/01/2008

Cage Range: ALL

Date Range: ALL

Reasons For Removal: ALL

Removal Date Range: ALL

Treatment Groups: Include ALL

Study Gender: Male

TDMSE Version: 2.1.0

Date Report Requested: 06/29/2009

Time Report Requested: 16:30:06 First Dose M/F: 07/10/03 / NA

Species/Strain: MICE/B6C3F1/NCTR

Route: IN-UTERO

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Time Report Requested: 16:30:06

First Dose M/F: 07/10/03 / NA

Date Report Requested: 06/29/2009

C57BL/6N XC3H/HEN MTV-NCTR MICE MALE	AZT-H to 0	AZT-M to 0	AZT-L to 0	AZT-H/3TC-H to 0	AZT-M/3TC-M to 0	AZT-L/3TC-L to
isposition Summary						
Animals Initially in Study	48	48	48	48	48	51
Early Deaths Moribund Sacrifice	8	5	8	6	5	7 1
Natural Death Survivors	2	3		5	4	1
Moribund Sacrifice Natural Death	1 1	1 1			1	3
Terminal Sacrifice	35	38	39	34	35	39
Harvest Animals Examined Microscopically	1 48	48	1 48	3 48	3 48	1 51
LIMENTARY SYSTEM						
Gallbladder Vacuolization Cytoplasmic	(45)	(44)	(48)	(44)	(42)	(49)
Epithelium, Hyperplasia Intestine Large, Cecum	(45)	(45)	(48)	1 [2.0] (43)	(45)	(50)
Hyperplasia, Lymphoid		1 [2.0]	2 [2.0]	2 [2.0]	5 [1.8]	2 [2.0]
Intestine Large, Colon Hyperplasia, Lymphoid	(45)	(46)	(48)	(44) 1 [2.0]	(45)	(50)
Inflammation, Chronic Active Ulcer				1 [2.0]	1 [2.0] 1 [4.0]	
Intestine Large, Rectum Anus, Hemorrhage Anus, Inflammation, Chronic Anus, Necrosis	(45)	(45)	(48) 1 [3.0] 1 [4.0] 1 [4.0]	(43)	(45)	(50)
Intestine Small, Duodenum	(45)	(45)	(48)	(43)	(44)	(50)
Hyperplasia, Lymphoid Infiltration Cellular, Plasma Cell Infiltration Cellular, Polymorphonuclear	1 [3.0]		1 [2.0]			1 [2.0]
Inflammation, Chronic Active Epithelium, Hyperplasia			1 [3.0]		1 [3.0]	
Intestine Small, Ileum Hyperplasia, Lymphoid Infiltration Cellular, Polymorphonuclear Inflammation, Suppurative	(45)	(45)	(48)	(43) 1 [2.0]	(45)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: IN-UTERO

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH **AVERAGE SEVERITY GRADES[b]**

AZT/Drug Combinations Transplacental Carcinogenesis Study **CAS Number:** AIDSTHERAPEU

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

Time Report Requested: 16:30:06 First Dose M/F: 07/10/03 / NA

Date Report Requested: 06/29/2009

S/Otrain. MIGE/BOOST 1/NOTIX					Lab. NOTK	
C57BL/6N XC3H/HEN MTV-NCTR MICE MALE	AZT-H to 0	AZT-M to 0	AZT-L to 0	AZT-H/3TC-H to 0	AZT-M/3TC-M to 0	AZT-L/3TC-L to
Inflammation, Chronic Active						
Intestine Small, Jejunum Hyperplasia, Lymphoid	(45)	(44)	(48)	(43)	(46)	(50)
Inflammation, Chronic Active	1 [2.0]					1 [2.0]
Liver	(46)	(47)	(48)	(46)	(48)	(51)
Angiectasis	. ,	, ,	, ,	, ,	1 [3.0]	
Basophilic Focus	4	6	2	4	5	6
Basophilic Focus, Multiple					1	
Cholangiofibrosis						
Clear Cell Focus				1		1
Clear Cell Focus, Multiple						
Cyst						1 [2.0]
Cyst Multilocular						
Eosinophilic Focus	1		4	2	2	3
Eosinophilic Focus, Multiple				1		
Fatty Change		1 [3.0]				
Fibrosis					1 [4.0]	
Focal Cellular Change						
Hematopoietic Cell Proliferation	1 [2.0]					3 [1.7]
Hepatodiaphragmatic Nodule						
Infiltration Cellular, Lymphocyte	1 [1.0]	3 [1.0]	4 [1.3]	3 [1.0]	4 [1.5]	4 [1.0]
Inflammation, Chronic		1 [3.0]				
Inflammation, Chronic Active	1 [1.0]		2 [1.5]	1 [1.0]	1 [4.0]	1 [2.0]
Mineralization			1 [1.0]		_	
Mixed Cell Focus				1	2	
Necrosis	4 [3.8]	2 [3.5]	2 [2.5]	2 [4.0]	2 [2.5]	
Tension Lipidosis	10 [1.5]	11 [1.3]	12 [1.1]	10 [1.3]	6 [1.7]	8 [1.3]
Vacuolization Cytoplasmic	5 [1.0]	1 [1.0]	2 [1.5]	3 [1.0]		4 [1.3]
Oval Cell, Hyperplasia	(2)	440	(=)	(2)	440	(=)
Mesentery	(3)	(1)	(2)	(0)	(1)	(2)
Hemorrhage						
Necrosis	4.54.01		4.54.01		4.54.03	0.50.51
Fat, Necrosis	1 [4.0]	(40)	1 [4.0]	(45)	1 [4.0]	2 [3.5]
Pancreas	(46)	(46)	(48)	(45)	(45)	(50)
Cyst			1 [4.0]		1 [4.0]	
Cytoplasmic Alteration						
Edema						
Fibrosis	4 [4 0]	0 [4 0]	0 [4 0]	0.[4.0]	E [4 0]	0.14.01
Infiltration Cellular, Lymphocyte	4 [1.0]	2 [1.0]	6 [1.2]	6 [1.0]	5 [1.0]	6 [1.0]
Inflammation, Chronic Active					1 [3.0]	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Route: IN-UTERO

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Time Report Requested: 16:30:06 First Dose M/F: 07/10/03 / NA

Date Report Requested: 06/29/2009

Lab: NCTR

Species/Strain: MICE/B6C3F1/NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE MALE	AZT-H to 0	AZT-M to 0	AZT-L to 0	AZT-H/3TC-H to 0	AZT-M/3TC-M to 0	AZT-L/3TC-L to
Acinus, Degeneration Salivary Glands	1 [1.0] (46)	5 [1.0] (46)	7 [1.3] (48)	4 [1.0] (44)	5 [1.2] (47)	6 [1.5] (50)
Fibrosis Infiltration Cellular, Lymphocyte Inflammation, Chronic Active	40 [1.3]	38 [1.4]	45 [1.3]	38 [1.4]	1 [4.0] 41 [1.2] 1 [4.0]	44 [1.2]
Mineralization Stomach, Forestomach	(46)	(46)	(48)	(45)	(45)	(50)
Cyst Epithelial Inclusion Hyperkeratosis Hyperplasia Inflammation, Chronic Active		1 [2.0] 1 [1.0]		1 [3.0]		
Ulcer Epithelium, Hyperplasia Stomach, Glandular Degeneration	1 [2.0] (45)	1 [3.0] (44) 1 [1.0]	(48)	1 [2.0] (43)	(45)	1 [2.0] 2 [2.0] (50)
Infiltration Cellular, Polymorphonuclear Inflammation, Suppurative Inflammation, Chronic Active Necrosis		1 [1.0]	1 [2.0]		1 [2.0]	
Ulcer Epithelium, Hyperplasia Glands, Hyperplasia						2 [2.5]
Tongue	(0)	(0)	(0)	(1)	(0)	(0)
CARDIOVASCULAR SYSTEM						
Blood Vessel Hemorrhage Polyarteritis	(47)	(47)	(48)	(46) 1 [2.0]	(48)	(50)
Heart Cardiomyopathy Inflammation	(47)	(48) 1 [3.0]	(48) 2 [1.0]	(46)	(48) 2 [1.0]	(50) 1 [1.0]
Inflammation, Chronic Active Necrosis		1 [1.0]				
Polyarteritis Ventricle, Dilatation			1 [1.0]			2 [2.5]

ENDOCRINE SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Species/Strain: MICE/B6C3F1/NCTR

Route: IN-UTERO

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

AS Number: AIDSTHERAPEU

Date Report Requested: 06/29/2009

Time Report Requested: 16:30:06 First Dose M/F: 07/10/03 / NA

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE MALE	AZT-H to 0	AZT-M to 0	AZT-L to 0	AZT-H/3TC-H to 0	AZT-M/3TC-M to 0	AZT-L/3TC-L to
Adrenal Cortex	(47)	(45)	(48)	(45)	(46)	(50)
Accessory Adrenal Cortical Nodule	1		1	3	2	
Cyst				1 [1.0]		1 [3.0]
Depletion					0.10.01	
Hyperplasia	0.10.01		4 [4 0]	4 [4 0]	2 [2.0]	0.10.01
Hypertrophy	2 [3.0]		4 [1.8]	1 [1.0]	4 [1.8]	3 [2.0]
Inflammation, Chronic Active	20 [4 2]	22 [4 4]	20 [4 4]	24 [4 2]	26 [4 2]	27 [4 2]
Subcapsular, Hyperplasia Adrenal Medulla	38 [1.2]	33 [1.4]	38 [1.4]	34 [1.2]	36 [1.3]	37 [1.3]
Hyperplasia	(45)	(45)	(46)	(43)	(46)	(49)
Islets, Pancreatic	(47)	(48)	(48)	(45)	(44)	(50)
Hyperplasia	5 [1.2]	6 [2.0]	5 [1.4]	8 [1.8]	9 [1.4]	12 [1.6]
Parathyroid Gland	(43)	(41)	(37)	(41)	(37)	(45)
Cyst	(10)	1 [1.0]	1 [1.0]	(11)	(01)	(10)
Infiltration Cellular, Lymphocyte		. []	2 [2.0]		1 [2.0]	1 [1.0]
Pituitary Gland	(45)	(48)	(47)	(45)	(44)	(50)
Pars Distalis, Cyst	3 [1.0]	3 [1.7]	7 [1.0]	7 [1.3]	3 [1.3]	1 [1.0]
Pars Distalis, Hyperplasia	1 [2.0]		1 [1.0]	,	1 [1.0]	3 [1.0]
Thyroid Gland	(46)	(45)	(48)	(46)	(46)	(50)
Depletion	,	,	1 [3.0]	,	,	,
Ectopic Thymus	1			1	1 [2.0]	
Infiltration Cellular, Lymphocyte	1 [1.0]		1 [1.0]			
Inflammation, Chronic Active					1 [1.0]	
Polyarteritis						1 [1.0]
Follicle, Cyst		1 [3.0]				
Follicle, Degeneration	5 [1.2]	6 [1.5]	7 [1.7]	3 [1.7]	6 [1.7]	4 [1.0]
Follicular Cell, Hyperplasia						
ENERAL BODY SYSTEM						
Tissue NOS	(1)	(2)	(0)	(3)	(1)	(1)
Abdominal, Fibrosis						
Abdominal, Infiltration Cellular,						
Polymorphonuclear						
Abdominal, Inflammation, Granulomatous						
Abdominal, Inflammation, Chronic Active						

GENITAL SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: IN-UTERO

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

AZT/Drug Combinations Transplacental Carcinogenesis Study **CAS Number:** AIDSTHERAPEU

Species/Strain: MICE/B6C3F1/NCTR

First Dose M/F: 07/10/03 / NA

Lab: NCTR

Date Report Requested: 06/29/2009

Time Report Requested: 16:30:06

C57BL/6N XC3H/HEN MTV-NCTR MICE MALE	AZT-H to 0	AZT-M to 0	AZT-L to 0	AZT-H/3TC-H to 0	AZT-M/3TC-M to 0	AZT-L/3TC-L to
Coagulating Gland	(0)	(1)	(0)	(1)	(0)	(2)
Lumen, Dilatation		1 [3.0]		1 [2.0]		2 [2.5]
Epididymis	(46)	(45)	(48)	(45)	(46)	(50)
Atrophy						
Fibrosis						1 [2.0]
Hypospermia			1 [3.0]		1 [3.0]	4 [2.5]
Infiltration Cellular, Lymphocyte		3 [1.7]	2 [1.5]	2 [1.5]	2 [1.5]	1 [2.0]
Inflammation, Chronic			4.54.03		4 50 01	
Inflammation, Chronic Active			1 [1.0]		1 [3.0]	
Mineralization				4.50.03		
Polyarteritis			4 [0.0]	1 [2.0]	4 50 03	
Spermatocele			1 [2.0]		1 [3.0]	
Duct, Degeneration	(40)	(4.4)	(40)	(4.4)	(40)	(50)
Preputial Gland	(46)	(44)	(48)	(44)	(46)	(50)
Cyst	2 [2.5]	10 [2.1]	7 [2.6]	1 [3.0]	2 [2.0]	5 [2.2]
Degeneration	16 [2.9]	19 [2.7]	17 [2.9]	19 [3.1]	21 [2.9]	27 [2.9]
Infiltration Cellular, Lymphocyte	3 [1.3]	1 [2.0]	1 [1.0]	1 [1.0]	1 [1.0]	
Inflammation, Suppurative	0.10.01	7.50.41	2 [2.5]	2 [2.0]	0.10.01	4 [4 0]
Inflammation, Chronic Active	3 [2.0]	7 [2.1]	1 [2.0]	4 [1.5]	6 [2.2]	1 [1.0]
Bilateral, Cyst		4 [0 0]			1 [3.0]	4 [4 0]
Duct, Dilatation	4 [0.0]	1 [3.0]				1 [4.0]
Fat, Degeneration	1 [2.0]		4 [0 0]			
Fat, Necrosis	(4.4)	(40)	1 [3.0]	(44)	(40)	(50)
Prostate	(44)	(43)	(48)	(44)	(46)	(50)
Dilatation	E [4 O]	0.[4.4]	0 [4 0]	7 [4 4]	4 [4 0]	0.14.01
Infiltration Cellular, Lymphocyte	5 [1.0]	8 [1.1]	6 [1.2]	7 [1.1]	4 [1.0]	9 [1.0]
Inflammation, Suppurative Inflammation, Chronic Active					1 [2 0]	
Polyarteritis					1 [2.0]	
Seminal Vesicle	(46)	(46)	(48)	(45)	(AE)	(50)
Amyloid Deposition	(46)	(46)	(40)	(45)	(45)	(50)
Afriyold Deposition Atrophy	1 [2.0]			1 [2.0]	1 [3.0]	1 [2.0]
Infiltration Cellular, Lymphocyte	1 [2.0] 1 [1.0]			1 [2.0]	1 [3.0]	1 [2.0]
Inflammation, Chronic Active	1 [1.0]				1 [2.0]	
Lumen, Dilatation	3 [2.0]	3 [2.0]	1 [2.0]	5 [2.4]	3 [2.0]	2 [2.5]
Testes	(45)	(45)	(48)	(44)	3 [2.0] (45)	2 [2.5] (50)
Mineralization	(40)	(40)	(40)	(44)	(43)	(30)
Seminiferous Tubule, Degeneration	2 [2.0]	6 [1.5]	5 [2.0]	3 [1.7]	5 [2.0]	9 [2.3]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Species/Strain: MICE/B6C3F1/NCTR

Route: IN-UTERO

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Time Report Requested: 16:30:06 First Dose M/F: 07/10/03 / NA

Date Report Requested: 06/29/2009

Lab: NCTR

1 [4.0]

C57BL/6N XC3H/HEN MTV-NCTR MICE MALE	AZT-H to 0	AZT-M to 0	AZT-L to 0	AZT-H/3TC-H to 0	AZT-M/3TC-M to 0	AZT-L/3TC-L to
HEMATOPOIETIC SYSTEM						
Bone Marrow	(46)	(46)	(48)	(44)	(46)	(51)
Fibrosis	£ [0.0]	0.00	4 [0 0]	4 [0 0]	1 [1.0]	0.00
Hyperplasia Pigmentation	5 [2.2]	3 [2.0]	1 [2.0]	1 [2.0]	2 [3.0]	3 [3.0]
Lymph Node Hemorrhage	(1)	(7)	(4)	(3)	(4)	(3)
Axillary, Hyperplasia, Lymphoid Axillary, Infiltration Cellular, Histiocyte Axillary, Infiltration Cellular, Plasma Cell Axillary, Infiltration Cellular, Polymorphonuclear Inguinal, Hyperplasia, Lymphoid Inguinal, Infiltration Cellular, Plasma Cell Inguinal, Infiltration Cellular, Polymorphonuclear Inguinal, Pigmentation Lumbar, Hemorrhage Lumbar, Hyperplasia, Lymphoid	1 [4.0]	1 [2.0] 1 [2.0]	2 [3.5]	1 [2.0]		
Lumbar, Infiltration Cellular, Plasma Cell Mediastinal, Hyperplasia, Lymphoid Mediastinal, Infiltration Cellular, Histiocyte Mediastinal, Inflammation, Chronic Active		1 [2.0]		. (2-0)		
Pancreatic, Hyperplasia, Lymphoid Pancreatic, Infiltration Cellular, Histiocyte Pancreatic, Sinus, Dilatation Renal, Hemorrhage			1 [2.0]		1 [2.0]	
Renal, Hyperplasia, Lymphoid Renal, Infiltration Cellular, Histiocyte Renal, Infiltration Cellular, Plasma Cell Renal, Infiltration Cellular, Polymorphonuclear Renal, Inflammation, Chronic Active		1 [2.0]		1 [2.0]		
Lymph Node, Mandibular	(43)	(45)	(46)	(45)	(46)	(50)
Hemorrhage					, ,	
Hyperplasia, Lymphoid	6 [1.2]	9 [1.6]	9 [1.2]	9 [1.6]	4 [1.8]	9 [1.2]
Hyperplasia, Plasma Cell					4 [4 0]	

a - Number of animals examined microscopically at site and number of animals with lesion

Infiltration Cellular, Mast Cell

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: IN-UTERO

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Time Report Requested: 16:30:06
First Dose M/F: 07/10/03 / NA

Date Report Requested: 06/29/2009

Lab: NCTR

T-L to 0 AZT-H/3TC-H to 0 AZT-M/3TC-M to 0 AZT-L/3	.1-L/31C-L to
1 [2.0]	
(48) (44) (46) (5	(50)
	5 [1.8]
,[1.0] ,[1.7] +[2.0] 0[0 [1.0]
1 [2.0]	
	7 [2.1]
	34 [2.1]
	4 [2.8]
1 [2.0] 1 [2.0]	
	1 [3.0]
1 [2.0] 3 [2.0] 1 [2.0]	1 [2.0]
[2.0]	
	4 [2.3]
(48) (45) (47)	(50)
4 [4 0]	
1 [4.0]	
7 [2.7] 9 [3.1] 6 [2.7] 11	11 [3.3]
	19 [2.7]
1 [4.0]	19 [2.7]
	(48)
	25 [2.8]
	1 [2.0]
	3 [2.3]
8	43) (38) (43) [2.7] 21 [3.2] 20 [2.9]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: IN-UTERO

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH **AVERAGE SEVERITY GRADES[b]**

AZT/Drug Combinations Transplacental Carcinogenesis Study **CAS Number:** AIDSTHERAPEU

Species/Strain: MICE/B6C3F1/NCTR

First Dose M/F: 07/10/03 / NA

Lab: NCTR

Date Report Requested: 06/29/2009

Time Report Requested: 16:30:06

C57BL/6N XC3H/HEN MTV-NCTR MICE MALE	AZT-H to 0	AZT-M to 0	AZT-L to 0	AZT-H/3TC-H to 0	AZT-M/3TC-M to 0	AZT-L/3TC-L to
INTEGUMENTARY SYSTEM						
Skin Fibrosis Hemorrhage Hyperkeratosis	(46)	(48) 1 [4.0]	(48) 1 [4.0]	(46)	(48) 1 [4.0]	(50) 1 [4.0]
Inflammation, Suppurative Inflammation, Chronic Active Metaplasia, Osseous	1 [3.0]		1 [1.0]	1 [2.0] 1 [2.0]	1 [1.0] 1 [4.0]	
Mineralization Necrosis	1 [4.0]		1 [1.0]	1 [3.0]	. [9]	
Ulcer Epithelium, Hyperplasia	2 [4.0] 1 [1.0]		1 [2.0]	2 [2.0] 1 [1.0]	1 [2.0]	
MUSCULOSKELETAL SYSTEM						
Bone Skeletal Muscle	(0) (3)	(0) (4)	(1) (1)	(0) (0)	(0) (1)	(0) (0)
NERVOUS SYSTEM						
Brain, Cerebellum Autolysis Hemorrhage	(46)	(46)	(48)	(46) 1 [4.0] 1 [3.0]	(45)	(50)
Brain, Cerebrum Degeneration Gliosis	(46)	(46)	(48)	(45)	(45) 1 [2.0]	(50)
Mineralization Polyarteritis	26 [1.0]	25 [1.0]	16 [1.0]	18 [1.1]	1 [2.0] 22 [1.0]	29 [1.0]
RESPIRATORY SYSTEM						
Lung Autolysis	(47)	(46)	(48)	(48) 1 [4.0]	(47)	(50)
Congestion Crystals	1 [4.0] 3 [2.3]			1 [4 .0]	3 [2.7]	4 [2.0]
Hemorrhage Infiltration Cellular, Histiocyte		1 [4.0]	1 [2 0]			1 [2.0]
minitration Genulai, Mistocyte	3 [2.3]		1 [3.0]		5 [2.2]	6 [1.8]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: IN-UTERO

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Time Report Requested: 16:30:06 First Dose M/F: 07/10/03 / NA

Date Report Requested: 06/29/2009

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE MALE	AZT-H to 0	AZT-M to 0	AZT-L to 0	AZT-H/3TC-H to 0	AZT-M/3TC-M to 0	AZT-L/3TC-L to (
Infiltration Cellular, Lymphocyte Inflammation, Chronic Active Pigmentation		1 [1.0]	1 [1.0]	4 [1.0]	5 [1.4] 1 [4.0]	3 [1.0] 1 [2.0]
Alveolar Epithelium, Hyperplasia Nose Inflammation, Chronic Active	1 [2.0] (47)	2 [3.0] (48)	4 [1.8] (48)	(46)	2 [2.5] (46) 1 [2.0]	4 [1.5] (51)
Mucosa, Dysplasia Posterior To Upper Incisor, Dysplasia	1 [3.0]	1 [2.0]	4 [2.5]		1 [3.0] 1 [4.0]	6 [2.7]
SPECIAL SENSES SYSTEM						
Eye Cataract Degeneration	(45) 1 [3.0]	(43)	(48) 2 [1.5]	(43)	(45) 1 [1.0]	(50) 2 [3.5]
Bilateral, Cataract Cornea, Inflammation, Suppurative	1 [1.0]				1 [1.0]	1 [2.0] 1 [4.0]
Cornea, Inflammation, Chronic Active Cornea, Ulcer Retina, Degeneration	2 [1.5] 1 [2.0]					1 [4.0] 1 [4.0]
Harderian Gland Cyst Cyst Multilocular	(45)	(45)	(48)	(45)	(45)	(50) 1 [4.0]
Foreign Body Hyperplasia Infiltration Cellular, Lymphocyte Infiltration Cellular, Polymorphonuclear	3 [1.0]	2 [1.5]	8 [1.0]	3 [1.0]	1 [3.0] 5 [1.0] 1 [1.0]	3 [1.0]
Inflammation, Chronic Active Acinus, Degeneration			1 [1.0] 2 [1.5]		1 [3.0] 1 [4.0]	1 [1.0]
URINARY SYSTEM						
Kidney Amyloid Deposition	(46)	(45)	(48)	(44)	(46)	(50) 1 [4.0]
Cyst Fibrosis	1 [2.0]	3 [1.3]	1 [2.0]	2 [2.5]	3 [2.3] 1 [4.0]	. []
Hyaline Droplet Infiltration Cellular, Lymphocyte Inflammation, Suppurative	1 [2.0] 9 [1.0]	1 [3.0] 7 [1.6]	3 [1.0]	5 [1.6] 1 [4.0]	6 [1.3]	3 [1.0]
Inflammation, Chronic Active				. [0]	1 [4.0]	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Species/Strain: MICE/B6C3F1/NCTR

Route: IN-UTERO

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Date Report Requested: 06/29/2009

Time Report Requested: 16:30:06 First Dose M/F: 07/10/03 / NA

C57BL/6N XC3H/HEN MTV-NCTR MICE MALE	AZT-H to 0	AZT-M to 0	AZT-L to 0	AZT-H/3TC-H to 0	AZT-M/3TC-M to 0	AZT-L/3TC-L to (
Metaplasia, Osseous	3 [1.3]	1 [1.0]	2 [1.5]			
Necrosis				1 [4.0]		
Nephropathy	34 [1.2]	31 [1.3]	39 [1.3]	33 [1.1]	32 [1.2]	42 [1.3]
Polyarteritis		1 [2.0]		1 [1.0]		
Pelvis, Dilatation			1 [3.0]		1 [4.0]	
Urethra	(1)	(1)	(0)	(0)	(0)	(0)
Dilatation	1 [4.0]					
Bulbourethral Gland, Cyst						
Bulbourethral Gland, Hemorrhage		1 [2.0]				
Bulbourethral Gland, Necrosis						
Bulbourethral Gland, Epithelium,		1 [3.0]				
Hyperplasia						
Urinary Bladder	(46)	(45)	(48)	(45)	(46)	(50)
Infiltration Cellular, Lymphocyte	3 [1.3]	6 [1.2]	2 [1.0]	5 [1.0]	5 [1.0]	8 [1.0]
Inflammation, Chronic Active					1 [4.0]	
Polyarteritis						
Lumen, Dilatation	1 [4.0]	3 [3.3]	2 [3.0]	1 [4.0]	2 [3.5]	2 [2.5]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: IN-UTERO

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

First Dose M/F: 07/10/03 / NA

Date Report Requested: 06/29/2009

Time Report Requested: 16:30:06

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE MALE	AZTH/3TCH/NVPH/0	AZTM/3TCM/NVPM/0	AZTL/3TCL/NVPL/0	AZTH/3TCH/NFVH/0	AZTM/3TCM/NFVM/0	AZTL/3TCL/NFVL/
Disposition Summary						
Animals Initially in Study Early Deaths	50	48	48	15	51	48
Moribund Sacrifice Natural Death	18 2	10 2	8 1	6 1	5 2	6 3
Survivors Moribund Sacrifice	5	1	4		5 1	1
Natural Death Terminal Sacrifice Harvest	25	1 35	1 37 1	6 2	36 2	37 1
Animals Examined Microscopically	50	48	48	15	51	48
LIMENTARY SYSTEM						
Gallbladder Vacuolization Cytoplasmic Epithelium, Hyperplasia	(47)	(44)	(45)	(13)	(47)	(45)
Intestine Large, Cecum Hyperplasia, Lymphoid	(48)	(45) 1 [2.0]	(47) 6 [2.0]	(14) 2 [1.5]	(48) 2 [2.0]	(45) 1 [2.0]
Intestine Large, Colon Hyperplasia, Lymphoid Inflammation, Chronic Active Ulcer	(48)	(45)	(47)	(14)	(48)	(45)
Intestine Large, Rectum Anus, Hemorrhage Anus, Inflammation, Chronic Anus, Necrosis	(47)	(45)	(47)	(14)	(48)	(45)
Intestine Small, Duodenum Hyperplasia, Lymphoid Infiltration Cellular, Plasma Cell	(48)	(45)	(47)	(14)	(48) 1 [3.0]	(45)
Infiltration Cellular, Polymorphonuclear Inflammation, Chronic Active Epithelium, Hyperplasia Intestine Small, Ileum	(40)	(45)	1 [2.0] 1 [2.0]	(4.4)	(40)	(45)
Intestine Small, lleum Hyperplasia, Lymphoid Infiltration Cellular, Polymorphonuclear Inflammation, Suppurative	(48) 1 [2.0]	(45)	(47) 1 [2.0] 1 [2.0]	(14)	(48) 1 [2.0]	(45)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Route: IN-UTERO CAS Number: Species/Strain: MICE/B6C3F1/NCTR

Time Report Requested: 16:30:06

First Dose M/F: 07/10/03 / NA

Date Report Requested: 06/29/2009

C57BL/6N XC3H/HEN MTV-NCTR MICE MALE	AZTH/3TCH/NVPH/0	AZTM/3TCM/NVPM/0	AZTL/3TCL/NVPL/0	AZTH/3TCH/NFVH/0	AZTM/3TCM/NFVM/0	AZTL/3TCL/NFVL/
Inflammation, Chronic Active Intestine Small, Jejunum Hyperplasia, Lymphoid	(48)	1 [2.0] (45) 1 [4.0]	(47) 1 [2.0]	(14) 1 [2.0]	(48)	(45)
Inflammation, Chronic Active Liver	(48)	(47)	(48)	(15)	(50)	(48)
Angiectasis Basophilic Focus Basophilic Focus, Multiple	4 1	5	5 1		3	2 1
Cholangiofibrosis Clear Cell Focus Clear Cell Focus, Multiple Cyst			1		2 1	
Cyst Multilocular Eosinophilic Focus Eosinophilic Focus, Multiple	1 [3.0]	2	4	1	1	2
Fatty Change Fibrosis Focal Cellular Change Hematopoietic Cell Proliferation		4	1			1 [4.0]
Hepatodiaphragmatic Nodule Infiltration Cellular, Lymphocyte Inflammation, Chronic Inflammation, Chronic Active	1 [1.0] 1 [1.0]	1 4 [1.0]	3 [1.3] 1 [4.0]	3 [1.0]	3 [1.0] 2 [1.5]	6 [1.2] 3 [2.3]
Mineralization Mixed Cell Focus Necrosis Tension Lipidosis	2 [1.5] 8 [1.5]	11 [1.5]	1 [4.0] 10 [1.2]		1 2 [3.0] 7 [1.7]	2 [2.0] 13 [1.5]
Vacuolization Cytoplasmic Oval Cell, Hyperplasia	2 [1.0]	1 [2.0]	2 [1.5] 1 [2.0]		1 [1.0]	2 [1.0]
Mesentery Hemorrhage	(1)	(0)	(1)	(0)	(2)	(0)
Necrosis Fat, Necrosis	1 [4.0]				1 [4.0]	
Pancreas Cyst Cytoplasmic Alteration Edema	(48)	(45)	(47) 1 [4.0] 1 [1.0] 1 [2.0]	(15)	(49)	(45)
Fibrosis Infiltration Cellular, Lymphocyte Inflammation, Chronic Active	7 [1.0]	4 [1.0]	3 [1.0] 1 [4.0]	1 [2.0]	1 [4.0] 6 [1.0] 1 [4.0]	1 [4.0] 4 [1.0] 2 [4.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Species/Strain: MICE/B6C3F1/NCTR

Route: IN-UTERO

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH **AVERAGE SEVERITY GRADES[b]**

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Lab: NCTR

Date Report Requested: 06/29/2009

Time Report Requested: 16:30:06

First Dose M/F: 07/10/03 / NA

C57BL/6N XC3H/HEN MTV-NCTR MICE MALE	AZTH/3TCH/NVPH/0	AZTM/3TCM/NVPM/0	AZTL/3TCL/NVPL/0	AZTH/3TCH/NFVH/0	AZTM/3TCM/NFVM/0	AZTL/3TCL/NFVL
Acinus, Degeneration Salivary Glands Fibrosis	2 [1.0] (48)	3 [1.3] (45)	5 [1.4] (47)	2 [1.5] (15)	4 [2.0] (50)	5 [1.2] (46)
Infiltration Cellular, Lymphocyte Inflammation, Chronic Active	38 [1.3]	35 [1.3]	39 [1.3]	11 [1.3]	40 [1.3]	38 [1.1] 1 [4.0]
Mineralization Stomach, Forestomach Cyst Epithelial Inclusion	1 [1.0] (48)	(45)	(48)	(15)	(50)	(45) 1 [2.0]
Hyperkeratosis Hyperplasia Inflammation, Chronic Active Ulcer Epithelium, Hyperplasia Stomach, Glandular Degeneration Infiltration Cellular, Polymorphonuclear	3 [2.0] (47)	(45)	1 [2.0] 1 [2.0] 2 [2.0] (47) 2 [2.0]	(14)	1 [2.0] (48)	(45) 1 [2.0]
Inflammation, Suppurative Inflammation, Chronic Active Necrosis			1 [2.0]	1 [2.0]		1 [2.0]
Ulcer Epithelium, Hyperplasia Glands, Hyperplasia	3 [2.0]		1 [2.0] 1 [3.0]	1 [2.0] 1 [3.0]	1 [2.0]	
Tongue	(0)	(0)	(0)	(0)	(0)	(0)
ARDIOVASCULAR SYSTEM						
Blood Vessel Hemorrhage	(48)	(47)	(47)	(15)	(50)	(48)
Polyarteritis Heart Cardiomyopathy	(48)	(47)	(47) 2 [1.0]	1 [1.0] (15)	(50)	(48) 1 [1.0]
Inflammation Inflammation, Chronic Active Necrosis	1 [1.0]					1 [1.0]
Polyarteritis Ventricle, Dilatation				1 [2.0]		1 [2.0]

ENDOCRINE SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Route: IN-UTERO

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Time Report Requested: 16:30:06 First Dose M/F: 07/10/03 / NA

Date Report Requested: 06/29/2009

Lab: NCTR

Species/Strain: MICE/B6C3F1/NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE MALE	AZTH/3TCH/NVPH/0	AZTM/3TCM/NVPM/0	AZTL/3TCL/NVPL/0	AZTH/3TCH/NFVH/0	AZTM/3TCM/NFVM/0	AZTL/3TCL/NFVL/
Adrenal Cortex	(47)	(45)	(47)	(15)	(49)	(45)
Accessory Adrenal Cortical Nodule Cyst	3	4	1	(/	(1-7)	1
Depletion	1 [4.0]					
Hyperplasia						
Hypertrophy	1 [1.0]	2 [1.5]	3 [1.0]		2 [1.0]	4 [1.5]
Inflammation, Chronic Active			1 [4.0]			1 [4.0]
Subcapsular, Hyperplasia	33 [1.3]	37 [1.4]	38 [1.4]	12 [1.3]	29 [1.2]	36 [1.3]
Adrenal Medulla	(46)	(44)	(46)	(13)	(47)	(44)
Hyperplasia	1 [1.0]				1 [2.0]	
Islets, Pancreatic	(48)	(45)	(47)	(15)	(50)	(45)
Hyperplasia		9 [1.6]	8 [1.9]	1 [1.0]	9 [2.0]	6 [1.8]
Parathyroid Gland	(34)	(33)	(38)	(13)	(40)	(38)
Cyst			1 [1.0]			
Infiltration Cellular, Lymphocyte		2 [1.0]				
Pituitary Gland	(48)	(44)	(46)	(15)	(50)	(46)
Pars Distalis, Cyst			2 [1.5]		2 [1.5]	1 [2.0]
Pars Distalis, Hyperplasia	1 [1.0]	2 [2.5]	1 [1.0]		1 [1.0]	2 [1.5]
Thyroid Gland	(48)	(45)	(48)	(15)	(50)	(46)
Depletion						
Ectopic Thymus			1			
Infiltration Cellular, Lymphocyte	1 [1.0]		2 [1.0]	1 [1.0]	1 [1.0]	1 [1.0]
Inflammation, Chronic Active						
Polyarteritis				1 [2.0]		
Follicle, Cyst	1 [2.0]			1 [2.0]		2 [1.5]
Follicle, Degeneration	2 [1.5]	3 [2.0]	5 [1.6]	2 [2.0]	6 [1.2]	1 [1.0]
Follicular Cell, Hyperplasia					1 [1.0]	
ENERAL BODY SYSTEM						
Tissue NOS	(0)	(0)	(2)	(2)	(1)	(2)
Abdominal, Fibrosis	(-)	(=)	1 [4.0]	(-/	(· /	\ - /
Abdominal, Infiltration Cellular,			1 [4.0]			
Polymorphonuclear			F			
Abdominal, Inflammation, Granulomatous			1 [4.0]			
Abdominal, Inflammation, Chronic Active			1 [4.0]			

GENITAL SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: IN-UTERO

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Time Report Requested: 16:30:06

First Dose M/F: 07/10/03 / NA

Date Report Requested: 06/29/2009

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE MALE	AZTH/3TCH/NVPH/0	AZTM/3TCM/NVPM/0	AZTL/3TCL/NVPL/0	AZTH/3TCH/NFVH/0	AZTM/3TCM/NFVM/0	AZTL/3TCL/NFVL
Coagulating Gland	(0)	(1)	(1)	(0)	(0)	(1)
Lumen, Dilatation	` '	1 [3.0]	1 [2.0]	. ,	. ,	1 [4.0]
Epididymis	(48)	(45)	(47)	(15)	(50)	(45)
Atrophy			1 [3.0]			
Fibrosis			1 [2.0]			
Hypospermia	1 [3.0]	1 [3.0]	2 [4.0]	1 [3.0]	1 [2.0]	1 [3.0]
Infiltration Cellular, Lymphocyte		3 [2.3]	4 [1.5]		1 [1.0]	2 [1.5]
Inflammation, Chronic			1 [2.0]			
Inflammation, Chronic Active		1 [2.0]	1 [4.0]			1 [2.0]
Mineralization		1 [4.0]				
Polyarteritis				1 [2.0]		
Spermatocele		1 [4.0]	2 [3.5]			
Duct, Degeneration		1 [4.0]				
Preputial Gland	(48)	(44)	(48)	(15)	(50)	(47)
Cyst	5 [2.4]	8 [2.4]	3 [3.0]	2 [2.5]	4 [2.3]	2 [2.5]
Degeneration	14 [2.6]	22 [2.7]	27 [3.0]	6 [2.7]	20 [2.7]	21 [2.8]
Infiltration Cellular, Lymphocyte	1 [2.0]		3 [2.0]			2 [1.5]
Inflammation, Suppurative		1 [3.0]	3 [1.7]			
Inflammation, Chronic Active	2 [1.5]	3 [1.7]	2 [3.0]	1 [2.0]	7 [2.3]	2 [1.5]
Bilateral, Cyst					1 [2.0]	
Duct, Dilatation						
Fat, Degeneration						
Fat, Necrosis						
Prostate	(48)	(43)	(47)	(15)	(48)	(44)
Dilatation	,	` ,	` ,	,	2 [2.0]	,
Infiltration Cellular, Lymphocyte	3 [1.3]	2 [1.5]	4 [1.3]	3 [1.3]	9 [1.2]	3 [1.0]
Inflammation, Suppurative			1 [4.0]			
Inflammation, Chronic Active						1 [4.0]
Polyarteritis				1 [2.0]		
Seminal Vesicle	(49)	(45)	(48)	(15)	(49)	(46)
Amyloid Deposition	, ,	,	1 [4.0]	, ,	, ,	` ,
Atrophy	1 [3.0]		1 [3.0]			1 [2.0]
Infiltration Cellular, Lymphocyte						
Inflammation, Chronic Active			1 [2.0]			1 [2.0]
Lumen, Dilatation	3 [3.3]	1 [1.0]	7 [2.6]		3 [2.3]	5 [2.8]
Testes	(49)	(45)	(47)	(15)	(49)	(45)
Mineralization	1 [1.0]	\ /	, ,	` '	, ,	` '
Seminiferous Tubule, Degeneration	4 [2.3]	7 [1.7]	10 [2.0]	2 [2.0]	6 [2.5]	3 [2.3]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Species/Strain: MICE/B6C3F1/NCTR

Route: IN-UTERO

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Time Report Requested: 16:30:06

First Dose M/F: 07/10/03 / NA

Date Report Requested: 06/29/2009

C57BL/6N XC3H/HEN MTV-NCTR MICE MALE	AZTH/3TCH/NVPH/0	AZTM/3TCM/NVPM/0	AZTL/3TCL/NVPL/0	AZTH/3TCH/NFVH/0	AZTM/3TCM/NFVM/0	AZTL/3TCL/NFVL/
HEMATOPOIETIC SYSTEM						
Bone Marrow	(48)	(45)	(48)	(15)	(50)	(45)
Fibrosis	0.10.71	4 [0.0]		4 [0.0]	0.[0.5]	
Hyperplasia Pigmentation	3 [2.7]	1 [2.0]	1 [3.0]	1 [2.0]	2 [2.5]	
Lymph Node	(6)	(2)	(3)	(3)	(3)	(4)
Hemorrhage	(0)	(2)	(3)	(3)	1 [1.0]	(4)
Axillary, Hyperplasia, Lymphoid		1 [3.0]	1 [3.0]		1 [1.0]	
Axillary, Infiltration Cellular, Histiocyte		. [0.0]	. [0.0]			
Axillary, Infiltration Cellular, Plasma Cell			1 [3.0]			
Axillary, Infiltration Cellular,			1 [3.0]			
Polymorphonuclear						
Inguinal, Hyperplasia, Lymphoid	2 [2.0]	1 [1.0]	1 [3.0]	1 [2.0]	1 [2.0]	
Inguinal, Infiltration Cellular, Plasma Cell			1 [3.0]			
Inguinal, Infiltration Cellular,			1 [3.0]			
Polymorphonuclear	4 [0.0]					
Inguinal, Pigmentation	1 [2.0]					
Lumbar, Hemorrhage Lumbar, Hyperplasia, Lymphoid	1 [1.0]	1 [2.0]	1 [3.0]			
Lumbar, Infiltration Cellular, Plasma Cell	1 [1.0]	1 [2.0]	1 [3.0] 1 [3.0]			
Mediastinal, Hyperplasia, Lymphoid			1 [3.0]			
Mediastinal, Infiltration Cellular,						
Histiocyte						
Mediastinal, Inflammation, Chronic Active						1 [3.0]
Pancreatic, Hyperplasia, Lymphoid						11
Pancreatic, Infiltration Cellular, Histiocyte						
Pancreatic, Sinus, Dilatation						
Renal, Hemorrhage						
Renal, Hyperplasia, Lymphoid		1 [2.0]	1 [3.0]		1 [2.0]	
Renal, Infiltration Cellular, Histiocyte			4 50 01			
Renal, Infiltration Cellular, Plasma Cell			1 [3.0]			
Renal, Infiltration Cellular, Polymorphonuclear			1 [3.0]			
Renal, Inflammation, Chronic Active						1 [3.0]
Lymph Node, Mandibular	(47)	(45)	(46)	(14)	(49)	(46)
Hemorrhage	(77)	1 [2.0]	(40)	(17)	(30)	(40)
Hyperplasia, Lymphoid	4 [1.3]	13 [1.4]	10 [1.4]	2 [1.5]	10 [1.4]	4 [1.3]
Hyperplasia, Plasma Cell	. [•]	. • []	. • []	-[]	. • []	. [0]
Infiltration Cellular, Mast Cell						

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Species/Strain: MICE/B6C3F1/NCTR

Route: IN-UTERO

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Time Report Requested: 16:30:06

First Dose M/F: 07/10/03 / NA

Date Report Requested: 06/29/2009

C57BL/6N XC3H/HEN MTV-NCTR MICE MALE	AZTH/3TCH/NVPH/0	AZTM/3TCM/NVPM/0	AZTL/3TCL/NVPL/0	AZTH/3TCH/NFVH/0	AZTM/3TCM/NFVM/0	AZTL/3TCL/NFVL/
Infiltration Cellular, Plasma Cell		2 [1.5]	3 [2.0]			2 [2.0]
Infiltration Cellular, Polymorphonuclear			1 [2.0]			4.54.03
Inflammation, Chronic Active	4 [0 0]					1 [4.0]
Necrosis	1 [2.0]					
Pigmentation	1 [2.0]	(45)	(46)	(4.4)	(40)	(46)
Lymph Node, Mesenteric	(48)	(45)	(46)	(14)	(48)	(46)
Angiectasis Fibrosis	6 [2.0]	11 [2.1]	10 [1.8]	4 [2.3]	12 [1.8]	6 [1.5]
Hematopoietic Cell Proliferation			1 [2.0]			1 [4.0]
Hemorrhage	15 [1.8]	13 [1.8]	13 [1.9]	1 [2.0]	16 [2.0]	11 [1.8]
Hyperplasia, Lymphoid	19 [2.1]	21 [2.1]	29 [2.1]	6 [2.5]	31 [2.1]	25 [2.1]
Infiltration Cellular, Histiocyte	1 [2.0]	2 [2.5]	2 [2.0]	0 [2.0]	3 [2.3]	1 [2.0]
Infiltration Cellular, Mast Cell	1 [2.0]	2 [2.5]	2 [2.0]		3 [2.3] 1 [2.0]	1 [2.0]
Infiltration Cellular, Plasma Cell	2 [3.0]	1 [2.0]	3 [3.3]	2 [3.5]	3 [3.3]	1 [3.0]
Infiltration Cellular, Polymorphonuclear	1 [3.0]	1 [2.0]	2 [3.0]	2 [0.0]	0 [0.0]	1 [0.0]
Inflammation, Granulomatous	1 [0.0]		2 [0.0]			1 [4.0]
Inflammation, Chronic Active			1 [4.0]			1 [4.0]
Necrosis	1 [2.0]		. [•]			. [•]
Polyarteritis	. []			1 [3.0]		
Thrombosis		1 [2.0]		. [0.0]	1 [3.0]	
Sinus, Dilatation	5 [2.4]	5 [2.0]	8 [1.8]		5 [2.0]	8 [1.8]
Spleen	(48)	(45)	(47)	(15)	(49)	(45)
Accessory Spleen	, ,	,	,	(/	`1 ´	()
Angiectasis						
Atrophy	1 [3.0]					
Congestion						
Depletion Lymphoid			1 [4.0]			
Hematopoietic Cell Proliferation	12 [2.9]	8 [2.6]	7 [2.9]	8 [3.3]	10 [3.1]	5 [3.2]
Hyperplasia, Lymphoid	20 [2.2]	20 [2.3]	20 [2.4]	4 [2.3]	24 [2.1]	21 [2.6]
Inflammation, Chronic Active						1 [4.0]
Thymus	(38)	(37)	(39)	(12)	(44)	(35)
Atrophy	17 [2.6]	19 [2.7]	18 [2.8]	8 [2.6]	14 [2.6]	15 [2.8]
Cyst						
Hyperplasia, Lymphoid	1 [2.0]					
Infiltration Cellular, Plasma Cell			1 [3.0]			
Infiltration Cellular, Polymorphonuclear			1 [2.0]			
Inflammation, Chronic Active			1 [4.0]			
Necrosis	1 [3.0]					

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: IN-UTERO

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

AZT/Drug Combinations Transplacental Carcinogenesis Study

Species/Strain: MICE/B6C3F1/NCTR

CAS Number: AIDSTHERAPEU

Time Borrert Borrert de 40.00.00

Time Report Requested: 16:30:06 First Dose M/F: 07/10/03 / NA

Date Report Requested: 06/29/2009

C57BL/6N XC3H/HEN MTV-NCTR MICE MALE	AZTH/3TCH/NVPH/0	AZTM/3TCM/NVPM/0	AZTL/3TCL/NVPL/0	AZTH/3TCH/NFVH/0	AZTM/3TCM/NFVM/0	AZTL/3TCL/NFVL
INTEGUMENTARY SYSTEM						
Skin Fibrosis Hemorrhage	(48) 2 [3.5]	(48)	(47) 2 [3.5]	(15)	(51) 1 [4.0]	(48) 1 [2.0]
Hyperkeratosis Inflammation, Suppurative Inflammation, Chronic Active Metaplasia, Osseous	2 [2.5] 3 [2.0]	1 [2.0]		1 [3.0]	1 [2.0]	1 [1.0]
Mineralization Necrosis Ulcer Epithelium, Hyperplasia	5 [2.6] 2 [2.0]	1 [2.0]		1 [3.0]	1 [2.0]	1 [2.0]
MUSCULOSKELETAL SYSTEM						
Bone Skeletal Muscle	(0) (0)	(0) (0)	(0) (0)	(0) (0)	(0) (1)	(1) (0)
NERVOUS SYSTEM						
Brain, Cerebellum Autolysis	(48)	(47)	(47)	(15)	(50)	(46)
Hemorrhage Brain, Cerebrum Degeneration	(48)	(47)	(47)	(15)	(50)	(46)
Gliosis Mineralization Polyarteritis	15 [1.0]	27 [1.0]	20 [1.0]	3 [1.0] 1 [2.0]	17 [1.0]	23 [1.1]
RESPIRATORY SYSTEM						
Lung Autolysis	(48)	(45)	(47)	(15)	(50)	(47)
Congestion Crystals		1 [3.0]	1 [4.0]	1 [4.0]	1 [2.0] 2 [3.0]	2 [3.5]
Hemorrhage Infiltration Cellular, Histiocyte		1 [3.0]		2 [2.5]	2 [3.0]	2 [3.5]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: IN-UTERO

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Time Report Requested: 16:30:06 First Dose M/F: 07/10/03 / NA

Date Report Requested: 06/29/2009

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE MALE	AZTH/3TCH/NVPH/0	AZTM/3TCM/NVPM/0	AZTL/3TCL/NVPL/0	AZTH/3TCH/NFVH/0	AZTM/3TCM/NFVM/0	AZTL/3TCL/NFVL/
Infiltration Cellular, Lymphocyte Inflammation, Chronic Active Pigmentation	3 [1.7]	2 [1.5]	2 [1.5] 1 [4.0]	3 [1.3]	3 [2.0]	4 [1.0] 1 [4.0]
Alveolar Epithelium, Hyperplasia Nose Inflammation, Chronic Active	1 [1.0] (49)	2 [2.5] (46)	2 [1.0] (47)	2 [3.0] (15)	1 [2.0] (51)	(47)
Mucosa, Dysplasia Posterior To Upper Incisor, Dysplasia		2 [4.0]	2 [3.0]		1 [2.0]	4 [2.5]
SPECIAL SENSES SYSTEM						
Eye Cataract	(48)	(45)	(47) 2 [2.5]	(14)	(49)	(45)
Degeneration Bilateral, Cataract Cornea, Inflammation, Suppurative		1 [4.0]	1 [1.0]			
Cornea, Inflammation, Chronic Active Cornea, Ulcer			1 [1.0]			1 [3.0] 1 [3.0]
Retina, Degeneration Harderian Gland Cyst	(48)	(45)	(47)	(14)	(50)	(45)
Cyst Multilocular Foreign Body Hyperplasia	1 [4.0]			1		
Infiltration Cellular, Lymphocyte Infiltration Cellular, Polymorphonuclear	9 [1.1]	2 [1.5]	1 [1.0]	3 [1.0]	4 [1.0]	3 [1.0]
Inflammation, Chronic Active Acinus, Degeneration			1 [2.0] 1 [2.0]	2 [1.5]	1 [2.0] 1 [3.0]	2 [2.0]
URINARY SYSTEM						
Kidney Amyloid Deposition	(48)	(45)	(47) 1 [4.0]	(14)	(49)	(46)
Cyst Fibrosis	3 [2.3]	3 [1.7]	1 [2.0]			3 [1.7] 1 [4.0]
Hyaline Droplet Infiltration Cellular, Lymphocyte Inflammation, Suppurative	7 [1.0]	9 [1.2]	2 [1.5]	1 [2.0]	3 [1.0]	5 [1.0]
Inflammation, Suppurative Inflammation, Chronic Active			1 [4.0]			2 [3.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

TDMS No. 20311 - 01
Test Type: CHRONIC

Species/Strain: MICE/B6C3F1/NCTR

Route: IN-UTERO

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Date Report Requested: 06/29/2009

Time Report Requested: 16:30:06 First Dose M/F: 07/10/03 / NA

C57BL/6N XC3H/HEN MTV-NCTR MICE MALE	AZTH/3TCH/NVPH/0	AZTM/3TCM/NVPM/0	AZTL/3TCL/NVPL/0	AZTH/3TCH/NFVH/0	AZTM/3TCM/NFVM/0	AZTL/3TCL/NFVL/0
Metaplasia, Osseous				1 [2.0]	1 [1.0]	3 [1.3]
Necrosis						
Nephropathy Polyarteritis	32 [1.2]	31 [1.1]	38 [1.3]	12 [1.3] 1 [2.0]	41 [1.3]	35 [1.1]
Pelvis, Dilatation		1 [2.0]	1 [4.0]	. [=.0]		1 [3.0]
Urethra	(0)	(0)	(0)	(0)	(0)	(2)
Dilatation	. ,	` ,	. ,	,	, ,	. ,
Bulbourethral Gland, Cyst						
Bulbourethral Gland, Hemorrhage						1 [2.0]
Bulbourethral Gland, Necrosis						
Bulbourethral Gland, Epithelium,						
Hyperplasia						
Urinary Bladder	(48)	(46)	(47)	(15)	(50)	(46)
Infiltration Cellular, Lymphocyte	7 [1.0]	11 [1.3]	7 [1.0]	2 [1.0]	4 [1.0]	2 [1.0]
Inflammation, Chronic Active			1 [4.0]			
Polyarteritis				1 [1.0]		
Lumen, Dilatation	3 [3.7]	1 [3.0]	1 [4.0]	2 [2.5]	5 [3.2]	2 [3.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Route: IN-UTERO

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Time Report Requested: 16:30:06

Date Report Requested: 06/29/2009

First Dose M/F: 07/10/03 / NA Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE MALE	SOLVENT to 0
Disposition Summary	
Animals Initially in Study	65
Early Deaths Moribund Sacrifice	4
Natural Death	2
Survivors	
Moribund Sacrifice	10
Natural Death Terminal Sacrifice	1
Harvest	46 2
Animals Examined Microscopically	65
ALIMENTARY SYSTEM	
Gallbladder	(59)
Vacuolization Cytoplasmic	1 [3.0]
Epithelium, Hyperplasia	
Intestine Large, Cecum	(63)
Hyperplasia, Lymphoid	6 [2.0]
Intestine Large, Colon Hyperplasia, Lymphoid	(63)
Inflammation, Chronic Active	
Ulcer	
Intestine Large, Rectum	(63)
Anus, Hemorrhage	
Anus, Inflammation, Chronic	
Anus, Necrosis Intestine Small, Duodenum	(63)
Hyperplasia, Lymphoid	(03)
Infiltration Cellular, Plasma Cell	
Infiltration Cellular, Polymorphonuclear	
Inflammation, Chronic Active	
	(00)
Epithelium, Hyperplasia	
Intestine Small, Ileum	(63)
	(63)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Species/Strain: MICE/B6C3F1/NCTR

Route: IN-UTERO

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Date Report Requested: 06/29/2009

Time Report Requested: 16:30:06 First Dose M/F: 07/10/03 / NA

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE MALE SOLVENT to 0

C37BL/ON XC3F/FIEN WITV-NCTR WICE WALE	SOLVENT 10 0
Inflammation, Chronic Active	
Intestine Small, Jejunum	(62)
Hyperplasia, Lymphoid	2 [2.5]
Inflammation, Chronic Active	
Liver	(65)
Angiectasis	_
Basophilic Focus	7
Basophilic Focus, Multiple	
Cholangiofibrosis Clear Cell Focus	1
Clear Cell Focus, Multiple	1
Cyst	1 [2.0]
Cyst Multilocular	. [2.0]
Eosinophilic Focus	1
Eosinophilic Focus, Multiple	
Fatty Change	
Fibrosis	
Focal Cellular Change	
Hematopoietic Cell Proliferation	
Hepatodiaphragmatic Nodule	0 [4 7]
Infiltration Cellular, Lymphocyte Inflammation, Chronic	3 [1.7]
Inflammation, Chronic Active	
Mineralization	
Mixed Cell Focus	
Necrosis	
Tension Lipidosis	12 [1.3]
Vacuolization Cytoplasmic	2 [1.5]
Oval Cell, Hyperplasia	
Mesentery	(4)
Hemorrhage	1 [4.0]
Necrosis Fat, Necrosis	1 [4.0] 1 [3.0]
Pancreas	(64)
Cyst	2 [3.0]
Cytoplasmic Alteration	2 [0.0]
Edema	
Fibrosis	
Infiltration Cellular, Lymphocyte	7 [1.1]
Inflammation, Chronic Active	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Route: IN-UTERO

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

AZT/Drug Combinations Transplacental Carcinogenesis Study

Species/Strain: MICE/B6C3F1/NCTR

CAS Number: AIDSTHERAPEU

Date Report Requested: 06/29/2009

Time Report Requested: 16:30:06 First Dose M/F: 07/10/03 / NA

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE MALE	SOLVENT to 0
Acinus, Degeneration	6 [1.3]
Salivary Glands	(64)
Fibrosis Infiltration Cellular, Lymphocyte	54 [1.2]
Inflammation, Chronic Active	
Mineralization Stomach, Forestomach	(64)
Cyst Epithelial Inclusion	(O 1)
Hyperkeratosis	
Hyperplasia Inflammation, Chronic Active	
Ulcer	2 [2.0]
Epithelium, Hyperplasia Stomach, Glandular	2 [2.0] (63)
Degeneration	(63) 1 [1.0]
Infiltration Cellular, Polymorphonuclear	1 -1
Inflammation, Suppurative Inflammation, Chronic Active	2 [1.5]
Necrosis	2 [1.0]
Ulcer	4 [0.0]
Epithelium, Hyperplasia Glands, Hyperplasia	1 [2.0]
Tongue	(0)
CARDIOVASCULAR SYSTEM	
Blood Vessel	(65)
Hemorrhage	4 [4 0]
Polyarteritis Heart	1 [1.0] (65)
Cardiomyopathy	1 [3.0]
Inflammation	1 [2.0]
Inflammation, Chronic Active Necrosis	
Polyarteritis	2 [1.0]
Ventricle, Dilatation	

ENDOCRINE SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Species/Strain: MICE/B6C3F1/NCTR

Route: IN-UTERO

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Date Report Requested: 06/29/2009

Time Report Requested: 16:30:06 First Dose M/F: 07/10/03 / NA

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE MALE	SOLVENT to 0
Adrenal Cortex	(63)
Accessory Adrenal Cortical Nodule	1
Cyst	1 [1.0]
Depletion	
Hyperplasia	
Hypertrophy	6 [2.2]
Inflammation, Chronic Active	
Subcapsular, Hyperplasia	47 [1.3]
Adrenal Medulla	(63)
Hyperplasia	()
Islets, Pancreatic	(65)
Hyperplasia	7 [1.7]
Parathyroid Gland	(52)
Cyst	
Infiltration Cellular, Lymphocyte	(0.1)
Pituitary Gland	(61)
Pars Distalis, Cyst	0.54.53
Pars Distalis, Hyperplasia	2 [1.5]
Thyroid Gland	(64)
Depletion	
Ectopic Thymus	0 [4 0]
Infiltration Cellular, Lymphocyte	3 [1.3]
Inflammation, Chronic Active	
Polyarteritis	1 [2 0]
Follicle, Cyst	1 [3.0]
Follicle, Degeneration Follicular Cell, Hyperplasia	10 [1.4]
гошсим Сеп, пурегразм	
ENERAL BODY SYSTEM	
Tissue NOS	(1)
Abdominal, Fibrosis	
Abdominal, Infiltration Cellular,	
Polymorphonuclear	
Abdominal, Inflammation, Granulomatous Abdominal, Inflammation, Chronic Active	
ADDOMINAL, INHAMINATION, UNFONIC ACTIVE	

GENITAL SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Route: IN-UTERO

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Species/Strain: MICE/B6C3F1/NCTR

Time Report Requested: 16:30:06 First Dose M/F: 07/10/03 / NA

Date Report Requested: 06/29/2009

C57BL/6N XC3H/HEN MTV-NCTR MICE MALE	SOLVENT to 0	
Coagulating Gland	(2)	
Lumen, Dilatation	2 [3.0]	
Epididymis	(63)	
Atrophy	(66)	
Fibrosis		
Hypospermia	2 [2.5]	
Infiltration Cellular, Lymphocyte	3 [1.3]	
Inflammation, Chronic		
Inflammation, Chronic Active	1 [2.0]	
Mineralization		
Polyarteritis		
Spermatocele	1 [4.0]	
Duct, Degeneration	1 [2.0]	
Preputial Gland	(64)	
Cyst	4 [2.8]	
Degeneration	32 [2.8]	
Infiltration Cellular, Lymphocyte	1 [2.0]	
Inflammation, Suppurative	0.10.01	
Inflammation, Chronic Active	6 [2.0]	
Bilateral, Cyst		
Duct, Dilatation		
Fat, Degeneration Fat, Necrosis		
Prostate	(64)	
Dilatation	(U 4)	
Infiltration Cellular, Lymphocyte	9 [1.0]	
Inflammation, Suppurative	5 [1.0]	
Inflammation, Chronic Active		
Polyarteritis	1 [2.0]	
Seminal Vesicle	(63)	
Amyloid Deposition	\ /	
Atrophy	1 [2.0]	
Infiltration Cellular, Lymphocyte	• •	
Inflammation, Chronic Active		
Lumen, Dilatation	8 [2.5]	
Testes	(64)	
Mineralization		
Seminiferous Tubule, Degeneration	7 [1.6]	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Route: IN-UTERO

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH **AVERAGE SEVERITY GRADES[b]**

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Date Report Requested: 06/29/2009

Time Report Requested: 16:30:06 First Dose M/F: 07/10/03 / NA

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE MALE **SOLVENT to 0**

HEM

EMATOPOIETIC SYSTEM	
Bone Marrow Fibrosis	(64)
Hyperplasia Pigmentation	6 [2.7]
Lymph Node	(7)
Hemorrhage Axillary, Hyperplasia, Lymphoid	
Axillary, Infiltration Cellular, Histiocyte	
Axillary, Infiltration Cellular, Plasma Cell	
Axillary, Infiltration Cellular,	
Polymorphonuclear Inguinal, Hyperplasia, Lymphoid	
Inguinal, Infiltration Cellular, Plasma Cell	
Inguinal, Infiltration Cellular,	
Polymorphonuclear	
Inguinal, Pigmentation	4 [0 0]
Lumbar, Hemorrhage Lumbar, Hyperplasia, Lymphoid	1 [2.0] 3 [1.7]
Lumbar, Tryperplasia, Lymphold Lumbar, Infiltration Cellular, Plasma Cell	3[1.7]
Mediastinal, Hyperplasia, Lymphoid	2 [2.5]
Mediastinal, Infiltration Cellular,	1 [2.0]
Histiocyte	
Mediastinal, Inflammation, Chronic Active	4 [0 0]
Pancreatic, Hyperplasia, Lymphoid Pancreatic, Infiltration Cellular, Histiocyte	1 [2.0] 1 [2.0]
Pancreatic, Finitiation Celidiar, Fistiocyte Pancreatic, Sinus, Dilatation	1 [2.0] 1 [2.0]
Renal, Hemorrhage	1 [2.0]
Renal, Hyperplasia, Lymphoid	2 [1.5]
Renal, Infiltration Cellular, Histiocyte	1 [2.0]
Renal, Infiltration Cellular, Plasma Cell	
Renal, Infiltration Cellular, Polymorphonuclear	
Renal, Inflammation, Chronic Active	
Lymph Node, Mandibular	(63)
Hemorrhage	,
Hyperplasia, Lymphoid	9 [1.7]
Hyperplasia, Plasma Cell	1 [3.0]
Infiltration Cellular, Mast Cell	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

TDMS No. 20311 - 01
Test Type: CHRONIC

Route: IN-UTERO

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Species/Strain: MICE/B6C3F1/NCTR

Time Penart Peguested: 16:30:06

Time Report Requested: 16:30:06 First Dose M/F: 07/10/03 / NA

Date Report Requested: 06/29/2009

C57BL/6N XC3H/HEN MTV-NCTR MICE MALE	SOLVENT to 0
Infiltration Cellular, Plasma Cell Infiltration Cellular, Polymorphonuclear Inflammation, Chronic Active Necrosis Pigmentation	1 [2.0]
Lymph Node, Mesenteric	(63)
Angiectasis Fibrosis Hematopoietic Cell Proliferation	10 [2.1]
Hemorrhage	19 [1.8]
Hyperplasia, Lymphoid	37 [2.1]
Infiltration Cellular, Histiocyte	4 [2.5]
Infiltration Cellular, Mast Cell	1 [2.0]
Infiltration Cellular, Plasma Cell	2 [3.0]
Infiltration Cellular, Polymorphonuclear Inflammation, Granulomatous Inflammation, Chronic Active Necrosis Polyarteritis	1 [1.0]
Thrombosis	1 [2 0]
Sinus, Dilatation	1 [2.0] 8 [2.1]
Spleen	(63)
Accessory Spleen	(03)
Angiectasis	1 [2.0]
Atrophy Congestion Depletion Lymphoid	· [2.0]
Hematopoietic Cell Proliferation	11 [3.5]
Hyperplasia, Lymphoid Inflammation, Chronic Active	30 [2.4]
Thymus	(51)
Atrophy	23 [2.8]
Cyst	
Hyperplasia, Lymphoid	
Infiltration Cellular, Plasma Cell	
Infiltration Cellular, Polymorphonuclear	
Inflammation, Chronic Active	
Necrosis	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Species/Strain: MICE/B6C3F1/NCTR

Route: IN-UTERO

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Time Report Requested: 16:30:06

Date Report Requested: 06/29/2009

First Dose M/F: 07/10/03 / NA

C57BL/6N XC3H/HEN MTV-NCTR MICE MALE	SOLVENT to 0
INTEGUMENTARY SYSTEM	
Skin Fibrosis Hemorrhage	(65)
Hyperkeratosis Inflammation, Suppurative Inflammation, Chronic Active	1 [3.0] 1 [4.0] 1 [2.0]
Metaplasia, Osseous Mineralization Necrosis Ulcer	1 [3.0]
Epithelium, Hyperplasia	_
MUSCULOSKELETAL SYSTEM	
Bone Skeletal Muscle	(0) (0)
NERVOUS SYSTEM	
Brain, Cerebellum Autolysis Hemorrhage	(64)
Brain, Cerebrum Degeneration Gliosis	(64)
Mineralization Polyarteritis	35 [1.0]
RESPIRATORY SYSTEM	
Lung Autolysis	(64)
Congestion Crystals	1 [2.0] 3 [2.7]
Hemorrhage Infiltration Cellular, Histiocyte	3 [2.7]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Species/Strain: MICE/B6C3F1/NCTR

Route: IN-UTERO

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Date Report Requested: 06/29/2009

Time Report Requested: 16:30:06 First Dose M/F: 07/10/03 / NA

C57BL/6N XC3H/HEN MTV-NCTR MICE MALE	SOLVENT to 0			
Infiltration Cellular, Lymphocyte	3 [1.0]			
Inflammation, Chronic Active Pigmentation	1 [1.0]			
Alveolar Epithelium, Hyperplasia	4 [3.0]			
Nose Inflammation, Chronic Active	(65)			
Mucosa, Dysplasia	2 [2 5]			
Posterior To Upper Incisor, Dysplasia	2 [2.5]			
SPECIAL SENSES SYSTEM				
Eye	(62)			
Cataract Degeneration	1 [1.0]			
Bilateral, Cataract	1 [1.0]			
Cornea, Inflammation, Suppurative Cornea, Inflammation, Chronic Active				
Cornea, Ulcer				
Retina, Degeneration Harderian Gland	(64)			
Cyst	(04)			
Cyst Multilocular Foreign Body				
Hyperplasia				
Infiltration Cellular, Lymphocyte Infiltration Cellular, Polymorphonuclear	5 [1.0]			
Inflammation, Chronic Active	1 [1.0]			
Acinus, Degeneration				
JRINARY SYSTEM				
Kidney Amyloid Deposition	(64)			
Cyst	3 [2.0]			
Fibrosis Hyaline Droplet				
Infiltration Cellular, Lymphocyte	6 [1.0]			
Inflammation, Suppurative Inflammation, Chronic Active				
initianimation, Chronic Active				

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Species/Strain: MICE/B6C3F1/NCTR

Route: IN-UTERO

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

AZT/Drug Combinations Transplacental Carcinogenesis Study

CAS Number: AIDSTHERAPEU

Time Report Requested: 16:30:06

First Dose M/F: 07/10/03 / NA

Date Report Requested: 06/29/2009

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE MALE	SOLVENT to 0
Metaplasia, Osseous	
Necrosis	
Nephropathy	54 [1.3]
Polyarteritis	1 [2.0]
Pelvis, Dilatation	
Urethra	(1)
Dilatation	
Bulbourethral Gland, Cyst	1 [4.0]
Bulbourethral Gland, Hemorrhage	1 [4.0]
Bulbourethral Gland, Necrosis	1 [4.0]
Bulbourethral Gland, Epithelium,	
Hyperplasia	(05)
Urinary Bladder	(65)
Infiltration Cellular, Lymphocyte	3 [1.0]
Inflammation, Chronic Active	
Polyarteritis	0.12.21
Lumen, Dilatation	6 [3.3]

*** END OF MALE ***

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)